ArticleMolecules (Basel, Switzerland)2020
Characterization, in Vitro and in Vivo Evaluation of Naringenin-Hydroxypropyl-ß-Cyclodextrin Inclusion for Pulmonary Delivery.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Medicinally Privileged Natural Chalcones: Abundance, Mechanisms of Action, and Clinical Trials.International journal of molecular sciences · 2024Review
- Article
- Differences in tissue distribution ability of evodiamine and dehydroevodiamine are due to the dihedral angle of the molecule stereo-structure.Frontiers in pharmacology · 2023Article
- The Systems of Naringenin with Solubilizers Expand Its Capability to Prevent Neurodegenerative Diseases.International journal of molecular sciences · 2022Article
- Naringenin Nano-Delivery Systems and Their Therapeutic Applications.Pharmaceutics · 2021Review
- Technological evolution of cyclodextrins in the pharmaceutical field.Journal of drug delivery science and technology · 2021Review
- Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Naringenin, a flavonoid compound which exists abundantly in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.